SIMILAR EFFICACY OF EGFR TYROSINE KINASE INHIBITORS REGARDLESS OF TREATMENT SEQUENCE FOR THE PATIENTS WITH EGFR MUTATION-POSITIVE PULMONARY ADENOCARCINOMA

被引：0
|
作者：
Koo, Dong Hoe [1 ]
Kim, Kyu-Pyo [1 ]
Choi, Chang-Min [1 ]
Lee, Dae-Ho [1 ]
Lee, Jae Cheol [1 ]
Lee, Jung-Shin [1 ]
Jang, Se Jin [1 ]
Kim, Sang-We [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
Treatment sequence; Adenocarcinoma; EGFR mutation; Tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S409 / S410
页数：2
相关论文
共 50 条
  • [1] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Su-Hee Cho
    Lee Chun Park
    Jun Ho Ji
    Silvia Park
    Deok Won Hwang
    Ji Yean Lee
    Yoon-La Choi
    Jung-Ho Han
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 315 - 320
  • [2] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Cho, Su-Hee
    Park, Lee Chun
    Ji, Jun Ho
    Park, Silvia
    Hwang, Deok Won
    Lee, Ji Yean
    Choi, Yoon-La
    Han, Jung-Ho
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 315 - 320
  • [3] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Tatsuya Yoshida
    Genichiro Ishii
    Koichi Goto
    Kiyotaka Yoh
    Seiji Niho
    Shigeki Umemura
    Shingo Matsumoto
    Hironobu Ohmatsu
    Kanji Nagai
    Yuichiro Ohe
    Atsushi Ochiai
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1691 - 1700
  • [4] Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
    Yoshida, Tatsuya
    Ishii, Genichiro
    Goto, Koichi
    Yoh, Kiyotaka
    Niho, Seiji
    Umemura, Shigeki
    Matsumoto, Shingo
    Ohmatsu, Hironobu
    Nagai, Kanji
    Ohe, Yuichiro
    Ochiai, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (10) : 1691 - 1700
  • [5] Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
    Sung, Mike R.
    Tomasini, Pascale
    Le, Lisa W.
    Kamel-Reid, Suzanne
    Tsao, Ming-Sound
    Liu, Geoffrey
    Bradbury, Penelope A.
    Shepherd, Frances A.
    Li, Janice J. N.
    Feld, Ronald
    Leighl, Natasha B.
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (02):
  • [6] EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
    Dong-Hoe Koo
    Kyu-pyo Kim
    Chang-Min Choi
    Dae-Ho Lee
    Jae Cheol Lee
    Jung-Shin Lee
    Se Jin Jang
    Sang-We Kim
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 197 - 206
  • [7] EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
    Koo, Dong-Hoe
    Kim, Kyu-pyo
    Choi, Chang-Min
    Lee, Dae-Ho
    Lee, Jae Cheol
    Lee, Jung-Shin
    Jang, Se Jin
    Kim, Sang-We
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (01) : 197 - 206
  • [8] EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
    Kim, Edward S.
    Melosky, Barbara
    Park, Keunchil
    Yamamoto, Nobuyuki
    Yang, James C-H
    FUTURE ONCOLOGY, 2021, 17 (18) : 2395 - 2408
  • [9] Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors
    Honda, Yoshihiro
    Takigawa, Nagio
    Fushimi, Soichiro
    Ochi, Nobuaki
    Kubo, Toshio
    Ozaki, Saeko
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    LUNG CANCER, 2012, 78 (01) : 121 - 124
  • [10] Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
    Shah, Riyaz
    Lester, Jason F.
    CLINICAL LUNG CANCER, 2020, 21 (03) : E216 - E228
12345